No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home PRIVATE EQUITY

SCIENTISTS PIONEER DEVELOPMENT OF MULTI-DISEASE RAPID TESTS AS EDX MEDICAL PLC COMPLETES ACQUISITION OF HUTANO DIAGNOSTICS LTD

Cisionby Cision
September 27, 2023
Reading Time: 4 mins read
in PRIVATE EQUITY, UK&IRELAND
Share on FacebookShare on Twitter

CAMBRIDGE, England, Sept. 27, 2023 /PRNewswire/ — Scientists in Cambridge and Oxford are developing a new generation of rapid healthcare tests capable of detecting and characterising a wide range of diseases within minutes. The new, miniaturised tests are expected to enable the identification of up to 10 disease markers simultaneously.

EDX Medical Logo

 

These advanced ‘point-of-care’ tests will be used by health professionals wherever they work, to identify early signs and details of cancer, infections, and cardio-vascular conditions. 

Multiple assays can be combined on a single smartphone-readable device supporting real time clinical decision-making and leading to better outcomes for patients. 

The tests represent a major improvement over lateral flow test technology with multiple disease markers readable faster and at lower cost than laboratory assays. 

The new test device will contain an array of ultra-sensitive nano-scale ‘mini-tests’, each mini-test replacing a lateral flow or laboratory test. Accuracy, speed and security is further enhanced by the ability to read and interpret the results using smartphone camera technology, setting new standards for ‘point-of-care’ clinical testing.

EDX Medical Group PLC, based in Cambridge, described these new tests as ‘game-changers’ for patients and healthcare professionals.

EDX Medical made the announcement following the acquisition of Hutano Diagnostics Ltd, based in Oxford, UK and the establishment of a Point-of-Care Innovation team to expand and accelerate the range of the new tests and their integration with EDX smartphone expertise.

Hutano has a team of highly experienced scientists and collaborators at the University of Oxford at its laboratory in Oxford, where it was founded in 2018 by Atherton Mutombwera and Professor William James to disrupt the lateral flow test marketplace through innovative technology.

Professor Sir Chris Evans, OBE, founder of EDX Medical, said: “We are tremendously excited by the prospect of making the most advanced point of care tests available for the benefit of patients everywhere. This is a great joint endeavour by scientists at Oxford and Cambridge. Hutano has the ambition and technology to develop truly unique tests which, when combined with EDX chemistry and smartphone expertise, will generate game-changing new digital diagnostic products.”

Dr Mike Hudson, chief executive of EDX Medical, commented: “The combined expertise and resources of the group puts us in a unique position to fast-track the introduction of a number of clinically important products and establish a new ‘standard’ in point-of-care testing worldwide.”

Hutano Diagnostics Ltd Founder and CEO, Atherton Mutombwera, said: “Joining forces with EDX Medical Group PLC opens up a world of possibilities. It gives us access to the resources, expertise, and global reach necessary to usher in the age of digital point-of-care diagnostics. Together, we will be able to bring our innovations to a much broader audience and drive positive change in the healthcare landscape.” 

Notes for Editors:
Point-of-Care Testing encompasses a range of technologies, which are amenable to use outside of a testing laboratory. They are typically lower cost and provide a fast, reliable result although traditionally less detailed than a laboratory test. Advances in technology and materials, of which Hutano and EDX Medical are pioneers, are creating opportunities to deliver high performance point-of-care tests aligned with the demand for cost-effective rapid clinical testing.

About EDX Medical Group PLC (www.edxmedical.co.uk)
EDX Medical Group plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, and infectious diseases. The company is listed on the AQSE Growth Market (TIDM: EDX). EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

About Hutano
Hutano Diagnostics Ltd is developing an innovative, quantitative, multiplex Point of Care Testing Platform. The Platform enables multiple biomarker detection and quantification on the same device. Hutano’s intellectual property covers a range of target recognition elements including antibodies and novel synthetic elements enabling both improved performance and quantification. A robust pipeline of new products has been established with a focus on providing clinically useful data in real time.  

Logo – https://mma.prnewswire.com/media/1945224/3890407/edxmedical_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/scientists-pioneer-development-of-multi-disease-rapid-tests-as-edx-medical-plc-completes-acquisition-of-hutano-diagnostics-ltd-301940678.html

Read the orginal article: undefined

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

UK&IRELAND

British startup Mozart AI raises €616k for its AI-powered Digital Audio Workstation

July 1, 2025
FINTECH

Zango AI Emerges From Stealth, Raising $4.8m to Revolutionise Financial Compliance Systems with AI Agents

July 1, 2025
UK&IRELAND

London-based startup Privasee rebrands as Vera, expanding beyond privacy compliance

July 1, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post
Italy’s private debt & corporate finance weekly round-up. News from City Green Light, Fiee, RSI, Credito Sportivo, Finlombarda, Banca Sella, and more

Italy’s private debt & corporate finance weekly round-up. News from City Green Light, Fiee, RSI, Credito Sportivo, Finlombarda, Banca Sella, and more

Brussels-based proptech Izix secures €3 million Series A to optimize the use of office buildings’ parking lots

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart